Last year saw no movement on cannabinoid issues at federal level in the US, as CBD-Intel predicted, and it’s not looking too good for this year either – though some continued movement at state level on medical and recreational cannabis is expected at the least.
Overall our outlook on the regulation of cannabis in the US in 2021 provided more hits than misses. We correctly predicted that the Food and Drug Administration (FDA) would not make a legal pathway for CBD products in 2021 but we were slightly over-optimistic that Congress would pass some sort of federal cannabis reform.
Anthony focuses on regulatory developments and legal analysis in the US. Anthony has a BA in political science from North Carolina State University and a JD from Charleston School of Law (South Carolina), where he was a senior editor on the law review. He practised law for several years in the United States as a litigator.
Our Key Benefits
The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.
CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.
Stay informed of any legal and market change in the sector that impacts your organisation
Maximise resources by getting market and legal data analysis daily in one place
Make smart decisions by understanding how the regulatory and market landscape evolves
Anticipate risks in your decisions by monitoring regulatory changes that impact your organization
Thanks for getting in touch with us
Please leave your enquiry and we will get back to you within 24 hours